Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Diagnosis, Prediction, and Natural Course of HIV-1 Protease-




 

Lancet (06/19/99) Vol. 353, No. 9170, P. 2093

Australian researchers investigated the natural course of lipodystrophy associated with long-term therapy for HIV-1 infection that includes a protease inhibitor. The condition was measured by questionnaire, physical exams, and dual-energy x-ray absorptiometry. The study, which involved 113 patients who were taking HIV-1 protease inhibitors and 45 HIV-1 patients never treated with a protease inhibitor, found a 98 percent concordance between patients' reports of the presence or absence of lipodystrophy and physical exam. According to the researchers, weight prior to therapy, fasting triglyceride, and C-peptide concentrations early in treatment, and therapy length appear to be predictors of the severity of lipodystrophy. While the condition was common and progressive following nearly two years of treatment with protease inhibitors, it was not generally severe. Other common conditions were hyperlipidemia and impaired glucose tolerance.



 


Copyright © 1999 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in June 22, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.